Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12146008rdf:typepubmed:Citationlld:pubmed
pubmed-article:12146008lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0019004lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0005767lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0225340lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:12146008lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:12146008pubmed:issue7lld:pubmed
pubmed-article:12146008pubmed:dateCreated2002-7-30lld:pubmed
pubmed-article:12146008pubmed:abstractTextThe patient was a 54-year-old woman with recurrent urinary tract cancer. A CT of the lung showed multiple nodules after bil-nephroureterectomy, cystectomy and combination chemotherapy with cisplatin (CDDP) and epirubicin (EPI). As second line chemotherapy for the patient, TXL was administered. She was hemodialized after operation, and there are few reports about paclitaxel (TXL) therapy for hemodialysis (HD) patients. Peak blood TXL concentration, about 1,200 ng/ml, was achieved 6 hours after the administration of TXL. The blood TXL concentration was 41 ng/ml 24 h after the administration of TXL. However, the TXL therapy was not repeated because of unacceptable neurological side effects. An almost 40% shrinkage in the size of the metastatic lung nodule was obtained after 1 cycle of treatment.lld:pubmed
pubmed-article:12146008pubmed:languagejpnlld:pubmed
pubmed-article:12146008pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12146008pubmed:citationSubsetIMlld:pubmed
pubmed-article:12146008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12146008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12146008pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12146008pubmed:statusMEDLINElld:pubmed
pubmed-article:12146008pubmed:monthJullld:pubmed
pubmed-article:12146008pubmed:issn0385-0684lld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:TsudaSatoshiSlld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:EguchiJiroJlld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:NomataKoichir...lld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:SagaraYuziYlld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:ToubuSyohheiSlld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:HakariyaTomoa...lld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:NoguchiMitsur...lld:pubmed
pubmed-article:12146008pubmed:authorpubmed-author:KanetakaHiros...lld:pubmed
pubmed-article:12146008pubmed:issnTypePrintlld:pubmed
pubmed-article:12146008pubmed:volume29lld:pubmed
pubmed-article:12146008pubmed:ownerNLMlld:pubmed
pubmed-article:12146008pubmed:authorsCompleteYlld:pubmed
pubmed-article:12146008pubmed:pagination1247-50lld:pubmed
pubmed-article:12146008pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:meshHeadingpubmed-meshheading:12146008...lld:pubmed
pubmed-article:12146008pubmed:year2002lld:pubmed
pubmed-article:12146008pubmed:articleTitle[Feasibility and change in the level of blood paclitaxel concentration after paclitaxel therapy for a hemodialysis patient with cisplatin resistant metastatic transitional cell cancer].lld:pubmed
pubmed-article:12146008pubmed:affiliationDept. of Urology, Nagasaki University School of Medicine.lld:pubmed
pubmed-article:12146008pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12146008pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:12146008pubmed:publicationTypeCase Reportslld:pubmed